Login to Your Account



Elan's Former Neurex Product, Prialt, Hits Phase III Endpoint

By Cormac Sheridan


Wednesday, January 14, 2004
Elan Corp. plc aims to launch its non-opioid peptide-based analgesic Prialt "no later" than the first quarter of 2005, following news that the compound met its primary endpoint in a trial of 220 patients with severe chronic pain who had not obtained relief with other therapies. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription